Insmed Inc
$ 143.83
-0.45%
23 Apr - close price
- Market Cap 31,046,015,000 USD
- Current Price $ 143.83
- High / Low $ 145.43 / 142.06
- Stock P/E N/A
- Book Value 3.45
- EPS -6.41
- Next Earning Report 2026-05-14
- Dividend Per Share N/A
- Dividend Yield 0 %
- Next Dividend Date -
- ROA -0.29 %
- ROE -2.49 %
- 52 Week High 212.75
- 52 Week Low 63.81
About
Insmed Incorporated, a biopharmaceutical company, develops and markets therapies for patients with rare and serious diseases. The company is headquartered in Bridgewater, New Jersey.
Analyst Target Price
$212.50
Quarterly Earnings
| Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | Mar 2023 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported Date | 2026-02-19 | 2025-10-29 | 2025-08-07 | 2025-05-07 | 2025-02-20 | 2024-10-31 | 2024-08-08 | 2024-05-09 | 2024-02-22 | 2023-10-26 | 2023-08-03 | 2023-05-04 |
| Reported EPS | -1.54 | -1.75 | -1.7 | -1.42 | -1.32 | -1.27 | -1.94 | -1.06 | -1.28 | -1.11 | -1.78 | -1.17 |
| Estimated EPS | -1.17 | -1.32 | -1.3 | -1.2 | -1.23 | -1.22 | -1.27 | -1.23 | -1.15 | -1.13 | -1.13 | -1.11 |
| Surprise | -0.37 | -0.43 | -0.4 | -0.22 | -0.09 | -0.05 | -0.67 | 0.17 | -0.13 | 0.02 | -0.65 | -0.06 |
| Surprise Percentage | -31.6239% | -32.5758% | -30.7692% | -18.3333% | -7.3171% | -4.0984% | -52.7559% | 13.8211% | -11.3043% | 1.7699% | -57.5221% | -5.4054% |
Next Quarterly Earnings
| Mar 2026 | |
|---|---|
| Reported Date | 2026-05-14 |
| Fiscal Date Ending | 2026-03-31 |
| Estimated EPS | -0.92 |
| Currency | USD |
Next Dividend Records
| Dividend per share (year): | - |
| Dividend Yield | - |
| Next Dividend Date | - |
| Ex-Dividend Date | - |
Recent News: INSM
2026-04-23 11:10:25
Insmed Incorporated announced it will release its first-quarter 2026 financial results on Thursday, May 7, 2026. The company will host a conference call for investors on the same day at 8:00 a.m. ET to discuss the results and provide a business update, with call details provided for participation and replay access. Insmed is a global biopharmaceutical company dedicated to developing therapies for serious diseases.
2026-04-23 11:10:25
Insmed (Nasdaq: INSM) will release its first-quarter 2026 financial results and host a conference call on Thursday, May 7, 2026, at 8:00 a.m. ET. Management will discuss the financial results and provide a business update during the call. The live webcast will be available on Insmed's website, with a phone replay and archived webcast also accessible for a limited period.
2026-04-21 04:10:35
Insmed Inc focuses on developing therapies for rare pulmonary diseases, leveraging its lead product ARIKAYCE and a pipeline including TPIP for pulmonary arterial hypertension. The company targets niche markets with high unmet needs, benefiting from orphan drug designations and a specialized inhalation technology. Analysts view Insmed as a compelling hold, but investors should consider clinical trial risks and commercialization challenges.
2026-04-18 06:39:23
Insmed's Chair and CEO, William Lewis, sold 10,700 shares of company stock for over $1.54 million but also exercised options to acquire 10,699 shares. Following these transactions, Lewis directly and indirectly holds a significant number of shares, while Insmed faces mixed analyst sentiment due to positive developments for some products and setbacks in clinical trials.
2026-04-17 22:09:31
Insmed CEO William Lewis sold 10,699 shares of the company's stock on April 16th for approximately $1.54 million, reducing his stake by 3.43%. This sale aligns with a series of prior insider sales since January, totaling about 80,599 shares, all executed under a pre-arranged Rule 10b5-1 trading plan. Despite recent negative EPS, the biopharmaceutical company reported strong revenue growth, and analysts maintain a consensus "Buy" rating with an average target price of $213.23.
2026-04-17 21:09:31
INSMED Inc. CEO William Lewis exercised stock options for 10,699 shares on April 16, 2026, at exercise prices of $30.46 and $17.16 per share. On the same day, he sold all 10,699 shares in open-market transactions with weighted average prices between $142.39 and $146.02 per share, pursuant to a pre-arranged Rule 10b5-1 trading plan. After these transactions, Lewis directly holds 301,185 shares and indirectly holds an additional 233,924 shares through a trust.
